Go to
JCI Insight
Citations to this article
Barbara Terzic, … , Marc V. Fuccillo, Zhaolan Zhou
Published October 15, 2021
Citation Information: J Clin Invest. 2021;131(20):e143655. https://doi.org/10.1172/JCI143655.
Citation Information: J Clin Invest. 2021;131(20):e143655. https://doi.org/10.1172/JCI143655.
Abstract
CDKL5 deficiency disorder (CDD) is an early onset, neurodevelopmental syndrome associated with pathogenic variants in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5). CDKL5 has been implicated in neuronal synapse maturation, yet its postdevelopmental necessity and the reversibility of CDD-associated impairments remain unknown. We temporally manipulated endogenous Cdkl5 expression in male mice and found that postdevelopmental loss of CDKL5 disrupts numerous behavioral domains, hippocampal circuit communication, and dendritic spine morphology, demonstrating an indispensable role for CDKL5 in the adult brain. Accordingly, restoration of Cdkl5 after the early stages of brain development using a conditional rescue mouse model ameliorated CDD-related behavioral impairments and aberrant NMDA receptor signaling. These findings highlight the requirement of CDKL5 beyond early development, underscore the potential for disease reversal in CDD, and suggest that a broad therapeutic time window exists for potential treatment of CDD-related deficits.
Authors
Barbara Terzic, M. Felicia Davatolhagh, Yugong Ho, Sheng Tang, Yu-Ting Liu, Zijie Xia, Yue Cui, Marc V. Fuccillo, Zhaolan Zhou
Citation information
Citations to this article (36)
| Title and authors | Publication | Year |
|---|---|---|
|
Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal
Xie Song, Zijie Xia, Dayne Martinez, Bing Xu, Zachary Spitzer, Yanjie Zhang, Erin Nugent, Yugong Ho, Barbara Terzic, Zhaolan Zhou |
Cell reports. Medicine | 2025 |
|
Women With Genetic Epilepsies
Marques PT, Kaka N, Zulfiqar Ali Q, Rong M, Bui E, Andrade DM |
Neurology: Genetics | 2025 |
|
The dual role of PTPN22 in immune modulation and transplantation tolerance.
Goncu B, Gurol AO |
Human cell | 2025 |
|
De novo variants in CDKL1 and CDKL2 are associated with neurodevelopmental symptoms
Bereshneh AH, Andrews JC, Eberl DF, Bademci G, Borja NA, Bivona S, Chung WK, Yamamoto S, Wangler MF, McKee S, Tekin M, Bellen HJ, Kanca O |
American Journal of Human Genetics | 2025 |
|
USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms.
Koch I, Slovik M, Zhang Y, Liu B, Rennie M, Konz E, Cogne B, Daana M, Davids L, Diets IJ, Gold NB, Holtz AM, Isidor B, Mor-Shaked H, Neira Fresneda J, Niederhoffer KY, Nizon M, Pfundt R, Simon M, Stegmann A, Guillen Sacoto MJ, Wevers M, Barakat TS, Yanovsky-Dagan S, Atanassov BS, Toth R, Gao C, Bustos F, Harel T |
Life science alliance | 2024 |
|
Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain.
Silvestre M, Dempster K, Mihaylov SR, Claxton S, Ultanir SK |
Molecular Psychiatry | 2024 |
|
Overcoming genetic and cellular complexity to study the pathophysiology of X-linked intellectual disabilities.
Martinez D, Jiang E, Zhou Z |
Journal of Neurodevelopmental Disorders | 2024 |
|
Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome.
Liu J, Chen S, Huang G, Wen P, Zhou X, Wu Y |
Cellular and molecular life sciences : CMLS | 2024 |
|
Variable expression of MECP2, CDKL5, and FMR1 in the human brain: Implications for gene restorative therapies.
Zito A, Lee JT |
Proceedings of the National Academy of Sciences | 2024 |
|
Reversal of neurological defects in a mouse model of microcephaly-capillary malformation syndrome
Meixin Hu, Jun Li, Jingxin Deng, Chunxue Liu, Yingying Liu, Huiping Li, Weijun Feng, Xiu Xu |
Molecular therapy : the journal of the American Society of Gene Therapy | 2024 |
|
Unlock the potential: Auditory-evoked event-related potential (ERP) as a treatment-responsive biomarker for Rett syndrome
Medina J, Zhou Z |
Neurotherapeutics | 2024 |
|
The small steps that lead to big impact: translating therapeutics from idea to reality for the CDKL5 deficiency disorder community.
Jaksha A, Bishop M, Utley K, Grabenstatter HL |
Therapeutic advances in rare disease | 2024 |
|
Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder
Voronin G, Narasimhan J, Gittens J, Sheedy J, Lipari P, Peters M, DeMarco S, Cao L, Varganov Y, Kim MJ, Pear L, Fotouh E, Sinha S, Ray B, Wu MC, Yalamanchili P, Southgate C, Pick J, Saadipour K, Jung S, Lee J, Mollin A, Welch EM, Wu Z, Weetall M |
Molecular Therapy | 2024 |
|
A new knockin mouse carrying the E364X patient mutation for CDKL5 deficiency disorder: neurological, behavioral and molecular profiling
Quadalti C, Sannia M, Humphreys NE, Baldassarro VA, Gurgone A, Ascolani M, Zanella L, Giardino L, Gross CT, Croci S, Meloni I, Giustetto M, Renieri A, Lorenzini L, Calzà L |
Heliyon | 2024 |
|
Acute MeCP2 loss in adult mice reveals transcriptional and chromatin changes that precede neurological dysfunction and inform pathogenic cascade
Bajikar SS, Zhou J, O\u2019Hara R, Tirumala HP, Durham MA, Trostle AJ, Dias M, Shao Y, Chen H, Wang W, Yalamanchili HK, Wan YW, Banaszynski LA, Liu Z, Zoghbi HY |
Neuron | 2024 |
|
Revealing the complex role of CDKL5 in developmental epilepsy through a calcium channel related vision
Yan M, Guo X, Xu C |
Acta Epileptologica | 2024 |
|
A Potent and Selective CDKL5/GSK3 Chemical Probe is Neuroprotective
Ong HW, Liang Y, Richardson W, Lowry ER, Wells CI, Chen X, Silvestre M, Dempster K, Silvaroli JA, Smith JL, Wichterle H, Pabla NS, Ultanir SK, Bullock AN, Drewry DH, Axtman AD |
2023 | |
|
Allelic contribution of Nrxn1α to autism-relevant behavioral phenotypes in mice.
Xu B, Ho Y, Fasolino M, Medina J, O'Brien WT, Lamonica JM, Nugent E, Brodkin ES, Fuccillo MV, Bucan M, Zhou Z |
PLoS genetics | 2023 |
|
Comparison of evoked potentials across four related developmental encephalopathies.
Saby JN, Peters SU, Benke TA, Standridge SM, Swanson LC, Lieberman DN, Olson HE, Key AP, Percy AK, Neul JL, Nelson CA, Roberts TPL, Marsh ED |
Journal of Neurodevelopmental Disorders | 2023 |
|
Epilepsy-Related CDKL5 Deficiency Slows Synaptic Vesicle Endocytosis in Central Nerve Terminals
Kontaxi C, Ivanova D, Davenport EC, Kind PC, Cousin MA |
Journal of Neuroscience | 2023 |
|
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective
Ong HW, Liang Y, Richardson W, Lowry ER, Wells CI, Chen X, Silvestre M, Dempster K, Silvaroli JA, Smith JL, Wichterle H, Pabla NS, Ultanir SK, Bullock AN, Drewry DH, Axtman AD |
ACS Chemical Neuroscience | 2023 |
|
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1.
Chamoto K, Yaguchi T, Tajima M, Honjo T |
Nature reviews. Immunology | 2023 |
|
Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology
Castano A, Silvestre M, Wells CI, Sanderson JL, Ferrer CA, Ong HW, Lang Y, Richardson W, Silvaroli JA, Bashore FM, Smith JL, Genereux IM, Dempster K, Drewry DH, Pabla NS, Bullock AN, Benke TA, Ultanir SK, Axtman AD |
eLife | 2023 |
|
Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
Sampedro-Castañeda M, Baltussen LL, Lopes AT, Qiu Y, Sirvio L, Mihaylov SR, Claxton S, Richardson JC, Lignani G, Ultanir SK |
Nature Communications | 2023 |
|
Rett and Rett-related disorders: Common mechanisms for shared symptoms?
D'Mello SR |
Experimental biology and medicine (Maywood, N.J.) | 2023 |
|
CDKL5 sculpts functional callosal connectivity to promote cognitive flexibility
Awad PN, Zerbi V, Johnson-Venkatesh EM, Damiani F, Pagani M, Markicevic M, Nickles S, Gozzi A, Umemori H, Fagiolini M |
Molecular Psychiatry | 2023 |
|
Midbrain dopamine neurons arbiter OCD-like behavior
Jinwen Xue, Dandan Qian, Bingqian Zhang, Wei Li, Yifei Bao, Jingxuan Yang, Shi Qiu, Yi Fu, Shaoli Wang, Ti-Fei Yuan, Wei Lu |
Proceedings of the National Academy of Sciences | 2022 |
|
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment
W Hong, I Haviland, E Pestana-Knight, J Weisenberg, S Demarest, E Marsh, H Olson |
CNS Drugs | 2022 |
|
Flow blockage disrupts cilia-driven fluid transport in the epileptic brain.
Faubel RJ, Santos Canellas VS, Gaesser J, Beluk NH, Feinstein TN, Wang Y, Yankova M, Karunakaran KB, King SM, Ganapathiraju MK, Lo CW |
Acta Neuropathologica | 2022 |
|
CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development
Van Bergen NJ, Massey S, Quigley A, Rollo B, Harris AR, Kapsa RM, Christodoulou J |
Biochemical Society Transactions | 2022 |
|
Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency
Adhikari A, Buchanan FK, Fenton TA, Cameron DL, Halmai JA, Copping NA, Fink KD, Silverman JL |
Human Molecular Genetics | 2022 |
|
Active human full-length CDKL5 produced in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125
Colarusso A, Lauro C, Calvanese M, Parrilli E, Tutino ML |
Microbial cell factories | 2022 |
|
CDKL5 Deficiency Disorder (CDD)-Rare Presentation in Male.
Rodak M, Jonderko M, Rozwadowska P, Machnikowska-Sokołowska M, Paprocka J |
2022 | |
|
mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder
Gurgone A, Pizzo R, Raspanti A, Chiantia G, Devi S, Comai D, Morello N, Pilotto F, Gnavi S, Lupori L, Mazziotti R, Sagona G, Putignano E, Nocentini A, Supuran CT, Marcantoni A, Pizzorusso T, Giustetto M |
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | 2022 |
|
Therapeutic validation and targeting of signalling networks that are dysregulated in intellectual disability.
Bustos F, Findlay GM |
The FEBS journal | 2022 |
|
CDKL5 deficiency: a disorder of neuromaintenance
Peter Kind |
Journal of Clinical Investigation | 2021 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)